Lupus (SLE): vizsgálatok itt: Lengyelország
25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Bydgoszcz, Częstochowa, Katowice, Krakow, Lodz, Lublin, Nadarzyn, Nowa Sól, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 70 év
- People
- 245 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07430306 - 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Bydgoszcz, Katowice, Kielce, Krakow, Lodz, Ossy, Warsaw
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peoplePhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- Where
- Bydgoszcz, Bytom, Warsaw, Wroclaw
- Életkor
- 12 év to 100 év
- People
- 550 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06133972 · EU 2023-505929-14-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Bytom, Cracow, Lublin, Malbork, Rzeszow, Rzeszów, Warszawa, Zamość
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Cracow, Lodz, Poznan, Szczecin, Warsaw, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Where
- Gdansk
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Bydgoszcz, Bytom, Cracow, Katowice, Nadarzyn, Nowa Sol, Plonsk, Poznan, Warsaw
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Cracow, Janki, Katowice, Lublin, Poznan, Warsaw, Wroclaw
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - 2. fázisNot yet taking people in LengyelországA Trial of LAD603 in Patients with Systemic Lupus Erythematosus
- Where
- Cracow, Janki, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 20 worldwide
- Run by
- Almirall S.A.
See details and how to join2026-527200-24-00 · EU 2026-527200-24-00 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Bydgoszcz, Cracow, Poznan, Warsaw, Wrocław
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 3. fázisNot yet taking people in LengyelországRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Bydgoszcz, Cracow, Katowice, Kielce, Ozarowice, Warsaw
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - 1. fázisTaking peopleA Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Where
- Cracow, Warsaw
- Életkor
- 18 év to 70 év
- People
- 24 worldwide
- Run by
- Cullinan Therapeutics Inc.
See details and how to joinNCT06613360 · EU 2024-518780-36-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Bialystok, Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Warsaw, Wroclaw
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisNot yet taking people in LengyelországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Bydgoszcz, Krakow, Poznan
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Bialystok, Bydgoszcz, Bytom, Cracow, Malbork, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 3. fázisTaking peopleA Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Where
- Bydgoszcz, Cracow, Częstochowa, Katowice, Lodz, Lublin, Nadarzyn, Nowa Sol, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 113 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-523670-17-00 · EU 2025-523670-17-00 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Lodz, Warsaw, Wroclaw
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 1. fázisTaking peopleA trial to learn how safe anifrolumab is, how it moves throughout the body over time, and how it affects the body of adults with systemic lupus erythematosus
- Where
- Bydgoszcz, Cracow, Katowice, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 13 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526171-32-00 · EU 2026-526171-32-00 - 3. fázisTaking peopleEfficacy and Safety of Deucravacitinib Compared with Placebo in Participants with Active SLE (POETYK SLE-1)
- Where
- Bialystok, Bydgoszcz, Cracow, Katowice, Lublin, Nadarzyn, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 147 worldwide
- Run by
- Bristol-Myers Squibb Services Unlimited Company
See details and how to join2022-500699-76-00 · EU 2022-500699-76-00 - 3. fázisCsak meghívásosLong-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- Where
- Bialystok, Bydgoszcz, Cracow, Częstochowa, Katowice, Lodz, Lublin, Poznan, Poznań, Wrocław
- Életkor
- 18 év to 75 év
- People
- 680 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT06475742 · EU 2024-514354-67-00 - 3. fázisTaking peopleA Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
- Where
- Cracow, Katowice, Lodz, Opole, Poznan, Swiecie, Warsaw, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 300 worldwide
- Run by
- Viatris Innovation GmbH
See details and how to joinNCT07201129 · EU 2025-522984-14-00 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Bytom, Gdansk, Gliwice, Lodz
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Cracow, Poznan, Warsaw
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00 - 1. fázisTaking peopleA Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- Where
- Bialystok, Bydgoszcz, Cracow, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 65 év
- People
- 142 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT06576271 · EU 2024-514186-18-00 - 3. fázisNot yet taking people in LengyelországClinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)
- Where
- Gdansk, Katowice-Ochojec, Krakow, Warsaw
- Életkor
- 18 év and over
- People
- 90
- Run by
- Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher
See details and how to join2024-517753-27-01 · EU 2024-517753-27-01